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hat Makes Platelets Angry
iabetes, Fibrinogen,
besity, and Impaired
esponse to Antiplatelet Therapy?*
eepak L. Bhatt, MD, FACC
oston, Massachusetts
ariability of platelet response to drug therapy has been
tudied intensely in recent years, though the underlying
auses and appropriate actions remain unclear (1,2). It
ppears that both patient-specific and medication-specific
actors contribute to the variability of platelet activity and
esponse. Clopidogrel and its conversion to an active me-
abolite appear to follow a Gaussian distribution—the
lassic bell-shaped curve—in which most patients respond
ust fine, but at either extreme there may be patients who are
ypo- or hyper-responders (3). In theory, such outliers may
See page 1052
e prone to ischemic or bleeding complications and, there-
ore, identification of these patients has been thought to
arry potential clinical utility (4). Superimposed on variabil-
ty due to drug metabolism is the variation in platelet
ctivity that may occur in clinical situations such as acute
oronary syndromes or other states that may cause height-
ned platelet activity. Low levels of platelet inhibition after
ntiplatelet therapy have been repeatedly associated with an
levated risk of ischemic events, both with glycoprotein
Ib/IIIa inhibitors as well as with clopidogrel (5,6).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
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In this issue of the Journal, Ang et al. (7) provide great
nsight into determinants of variability in platelet response
o clopidogrel. Using a point-of-care measure of platelet
nhibition to clopidogrel, they confirm the usual distribution
f clopidogrel response variability in 157 patients with
ardiovascular disease. Using multivariable analysis, they
nd that diabetes mellitus, elevated fibrinogen levels, and
besity are all associated with diminished platelet inhibition.
nterestingly, there is a significant interaction between
iabetic status and fibrinogen, such that elevated fibrinogen
s predictive of lower platelet inhibition only in patients with
iabetes, but not in those without diabetes. Therefore, it
ppeared that the impaired response of the diabetic platelet
as, in part, mediated by (or at least associated with)
levated fibrinogen levels. Conversely, fibrinogen elevation
n a nondiabetic milieu did not affect the platelet response.
igher body mass index remained associated with impaired
latelet inhibition irrespective of fibrinogen levels.
A large body of evidence supports the contention that
iabetic patients have “angrier” platelets. While the etiology
f their increased platelet activation is multifactorial, the
onsequences are higher rates of ischemic complications in
hose with diabetes mellitus. More potent antiplatelet ther-
py appears to have a greater clinical benefit in diabetic
atients versus nondiabetic patients. This has been noted
ith both intravenous glycoprotein IIb/IIIa inhibitors and
denosine diphosphate receptor blockade (8–10). High
latelet reactivity in diabetic patients has been linked with a
reater risk of adverse outcomes (11). Potentially, increased
oses of clopidogrel, more potent agents such as prasugrel,
r novel agents in development may be of incremental
enefit (10,12,13).
Future studies will need to confirm whether fibrinogen is
ndeed a marker of impaired response to antiplatelet therapy in
iabetic patients. If so, measurement of fibrinogen levels in
iabetic patients could help guide the intensity of the
ntiplatelet regimen utilized. Also, if the interaction between
levated fibrinogen, diabetes, and impaired platelet response is
onfirmed in other studies, this might explain why some papers
ave reported an association between fibrinogen and cardio-
ascular risk, while others have not (14).
The relationship between obesity and impaired response
o antiplatelet therapy is also complex. On one level, it could
imply be an issue of underdosing of drugs. On another
evel, it could be the inflammatory state of obesity leading to
latelet activation (15). Adipose cells produce leptin, whose
eceptor has been identified on platelets. Endocannabinoids
lso play a role in regulation of obesity and have been
emonstrated to activate platelets. Thus, through these and
ther pathways, obesity could lead to increased platelet
ctivation and consequent impaired response to antiplatelet
reatment. Preliminary evidence already supports an associ-
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September 23, 2008:1060–1 Editorial Commenttion between elevated body mass index and diminished
esponse to antiplatelet therapy (16).
Additionally, there is abundant evidence that low body
ass index predisposes to bleeding complications associated
ith antiplatelet drugs (10,17). Again, this may relate either
o relative overdosing of antithrombotic medications or to
ower levels of baseline platelet activation in a lean patient
18). The study by Ang et al. (7) adds further evidence that
erhaps oral antiplatelet drugs should be dosed based on
eight. In the future, clinical trials will need to determine if
eight-based dosing of oral antiplatelet therapy might help
alance efficacy and safety. The TRILOGY ACS (TaRgeted
latelet Inhibition to cLarify the Optimal strateGy to
edicallY manage Acute Coronary Syndromes) trial (19) is
urrently examining 2 different maintenance doses of pra-
ugrel in patients depending on their weight and age.
While the relationships described by Ang et al. (7) are
ikely multifactorial and only now starting to be untangled,
here is a tantalizing potential to minimize ischemic and
leeding complications by dosage modification guided by
latelet response. This appealing theory is being tested in
ngoing studies such as in the GRAVITAS (Gauging
esponsiveness with A VerifyNow assay–Impact on
hrombosis And Safety) trial (20), which is measuring
oint-of-care antiplatelet response to clopidogrel and ran-
omizing patients to different intensity of platelet inhibition
ith clopidogrel. If such clinical investigation supports
herapeutic modification based on platelet response, then
outine point-of-care platelet function testing may be war-
anted. Based on the observations of Ang et al. (7),
djustment of dosage by diabetic status and body mass index
ay be particularly useful in individualizing therapy. Fur-
hermore, it would be a major contribution if future research
orroborates that fibrinogen truly is the link that makes
iabetic platelets angry.
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